Best peptides for immune support
For frequent infections, vaccine response, chronic infection, immune aging, inflammation control.
Reviewed by the amino101 editorial team. , first published .
Immune support is one of the few categories where the top pick is a licensed medicine with randomized trials, and one of the many where the bottom pick is a test tube finding with a forum following. Thymosin alpha-1 is approved in more than 30 countries and has a safety record across thousands of patients, which puts it in a different class from everything else here. Below it the evidence drops fast: a neuropeptide with mixed lung trials, an anti-inflammatory fragment with mouse data, a healing peptide that people confuse with the top pick, and an antimicrobial peptide that has never been injected into a person in a study. Modulating the immune system cuts both ways, so autoimmune conditions change the calculation for every compound on this list. Educational ranking only.
- 1Full guideThymosin Alpha-1Well researched
The clear first pick. Approved as Zadaxin abroad for hepatitis B and as a vaccine adjuvant, with randomized trials showing better antibody response in older adults and dialysis patients and a mortality trend in sepsis. Primes dendritic cells and T cells. Modest, inconsistent benefits and a clean safety profile.
Dosage0.5 to 1.6 mgFrequencytwice weekly, up to daily in short acute protocolsRouteSubcutaneous - 2Full guideVIPWell researched
An anti-inflammatory neuropeptide that shifts T cells toward a regulatory profile in cell and mouse work, with real trials as aviptadil for lung conditions and a small open label study for mold illness. Nasal, started low, with blood pressure and lipase to watch.
Dosage50 to 200 mcgFrequency1 to 4 times daily (nasal), starting at once dailyRouteIntranasal, Subcutaneous, Intravenous - 3Full guideKPVPreclinical only
Inflammation control rather than immune stimulation. The anti-inflammatory tail of alpha-MSH blunts NF-kB in cell studies and calms colitis and dermatitis in mice. No human trial. The pick when the problem is too much inflammation, not too little defense.
Dosage250 to 500 mcgFrequencyonce or twice dailyRouteOral, Subcutaneous, Intranasal, Topical - 4Full guideTB-500Limited research
Not an immune peptide, and on the list because it is confused with thymosin alpha-1 so often. A fragment of thymosin beta-4 for tissue repair. Shares a first name with the top pick and nothing else.
Dosage2 to 5 mgFrequencytwice weekly during loading, then weekly or every other weekRouteSubcutaneous, Intramuscular - 5Full guideLL-37Limited research
Last, with caution. The human antimicrobial peptide, with strong test tube data against bacteria and biofilms, one small topical trial, and no human safety data for injection. Causes significant injection site inflammation and drives autoimmune skin disease. Nobody who has read the data makes it a first move.
Dosage50 to 125 mcgFrequencyonce daily, or every other day if the injection site reactsRouteSubcutaneous, Topical
Thymosin alpha-1 is the answer for most people asking this question, at the trial dosage of 1.6 mg twice weekly or the lower 0.5 to 1 mg community range, judged over 2 to 6 months because there is nothing to feel in the first weeks. VIP is for the mold illness protocol specifically and KPV for the person whose immune problem is inflammation. TB-500 is here to stop a mislabeled purchase. LL-37 is the compound forums add on top, and the honest reading of its data says the risk is known and the benefit is not. Vitamin D, sleep and vaccination are the evidence based immune supports; the peptides are educational background rather than a plan.
Dosage at a glance
What appears in research and community protocols for each pick. Every number links to the full protocol table and calculator on the compound page.
| Peptide | Dosage | Frequency | Route | Cycle | First effects |
|---|---|---|---|---|---|
| Thymosin Alpha-1 | 0.5 to 1.6 mg | twice weekly, up to daily in short acute protocols | Subcutaneous | 4 to 12 weeks in community use; 6 months in the hepatitis B labeling | nothing to feel in the first weeks; immune markers and infection frequency are judged over 2 to 6 months |
| VIP | 50 mcg per spray, one spray in each nostril; 50 to 200 mcg per dosing session | 1 to 4 times daily (nasal), starting at once daily | Intranasal, Subcutaneous, Intravenous | 1 to 3 months at full dose | energy and cognitive clarity 1 to 3 weeks, inflammatory markers 4 to 8 weeks, full CIRS protocol 1 to 3 months |
| KPV | 250 to 500 mcg (injectable or nasal); 500 mcg to 1 mg (oral) | once or twice daily | Oral, Subcutaneous, Intranasal, Topical | 4 to 8 weeks | gut and skin inflammation 1 to 2 weeks, fuller effect 3 to 4 weeks |
| TB-500 | 2 to 5 mg | twice weekly during loading, then weekly or every other week | Subcutaneous, Intramuscular | 4 to 6 week loading phase, then maintenance or stop | flexibility and reduced stiffness 1 to 2 weeks, injury recovery 4 to 6 weeks |
| LL-37 | 50 to 125 mcg | once daily, or every other day if the injection site reacts | Subcutaneous, Topical | 2 to 6 weeks | injection site redness within hours; any wound or infection change is judged over 2 to 4 weeks, and only topical wound use has trial support |
Side effects to expect
- ▲Injection site redness, soreness or small lumps
- ▲Mild muscle aches or fatigue for a day after a dose
- ▲Low grade fever or chills in a small minority
- ▲Flushing, lightheadedness or rapid heart rate, especially at higher doses
- ▲Headache
- ▲Diarrhea or stomach upset from its secretory effect on the gut
- ▲Nausea, mostly with injectable use
- ▲Headache
- ▲Injection site irritation
- ▲Fatigue, lethargy or a head rush for a few hours after larger doses
- ▲Headache
- ▲Injection site redness or mild bruising
- ▲Injection site redness, swelling, warmth and pain, often significant
- ▲Welts or firm lumps at injection sites that last days
- ▲Fatigue or a flu like feeling after doses
Where to buy
All trusted vendors by countryVendors that passed our checks. Codes are optional and support the site.
Best peptides for immune support: frequently asked
What is the best peptide for immune support?
Thymosin alpha-1. It is a licensed drug in more than 30 countries with randomized trials in hepatitis B, sepsis and vaccine response, and consistent safety across thousands of patients. The approved dosage is 1.6 mg subcutaneously twice weekly; community protocols report 0.5 to 1.6 mg two to three times weekly for 4 to 12 weeks. The benefits in trials were modest, and the claims about curing chronic infections go beyond them.
Is thymosin alpha-1 the same as TB-500?
No, and this is the most common name mix up in the space. Thymosin alpha-1 is a 28 amino acid immune peptide; TB-500 is a short fragment of thymosin beta-4 used for injury recovery, with no immune effect. Both were first isolated from thymus extract and that is the only link. Vendors sometimes mislabel them, so read the vial; the full breakdown is at thymosin alpha-1 vs TB-500.
Is LL-37 safe to inject for immune support?
Nobody knows. The only human trial of LL-37 was topical on leg ulcers at low concentrations, and the highest concentration tested worked worse than the lower two. No study has injected it into people, there is no human pharmacokinetic data, and it causes redness, swelling and welts at most injection sites because its job is to recruit immune cells. It is implicated in psoriasis, rosacea and lupus. The pairing it usually appears in is examined at the thymosin alpha-1 and LL-37 stack.
Can peptides help with autoimmune disease?
This is where the direction matters. Thymosin alpha-1 raises Th1 activity and could in theory worsen lupus, multiple sclerosis or rheumatoid arthritis; no trial has tested it, and its label excludes transplant recipients. LL-37 is a known driver of autoimmune inflammation. KPV and VIP go the other way, dampening inflammation in mouse models, with no human autoimmune trial for either. Anyone with a diagnosed autoimmune condition has reason to be careful with every compound on this list; see peptides for inflammation for the anti-inflammatory side.
Does thymosin alpha-1 help with colds, long COVID or chronic fatigue?
There is no controlled evidence for any of these. Observational reports from Chinese hospitals during the pandemic suggested lower mortality in some patients who received it, but those were not randomized and later analyses were mixed. For everyday infections and fatigue the evidence is anecdote. The trial data cover hepatitis B, sepsis, vaccine response in poor responders, and melanoma alongside chemotherapy, which is a narrower list than the marketing.
Related reading
Soft tissue and tendon injury recovery
Skin, scar and post-procedure healing
Healing with inflammation and gut support
Gut lining repair and inflammation control
Immune support and chronic infection
Which healing peptide should you start with, and do you need both?
Both are gut peptides. One repairs, one calms inflammation. Which problem do you have?
Same first name, nothing else in common. Which thymosin do you actually want?
Dosage